SWOG Cancer Research Network — CureCurrent

How to interpret these research links

Connected source records

The exact organization name SWOG Cancer Research Network appears in 170 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials170

Recruiting shown12

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyNCT06769126 · lead sponsor · 2025-11-06

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)NCT06616584 · lead sponsor · 2025-05-22

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the BodyNCT06470243 · lead sponsor · 2024-11-27

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)NCT06116682 · lead sponsor · 2024-11-19

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)NCT06031688 · lead sponsor · 2024-08-08

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene MutationNCT05806515 · lead sponsor · 2024-03-01

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · lead sponsor · 2023-09-15

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)NCT05642572 · lead sponsor · 2023-05-05

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · lead sponsor · 2019-02-06

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerNCT03678025 · lead sponsor · 2018-09-24

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerNCT03723928 · lead sponsor · 2018-09-17

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityNCT03418961 · lead sponsor · 2017-11-01

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisNCT07578116 · lead sponsor · 2027-03-09

NOT_YET_RECRUITING

Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA TestingNCT07802626 · lead sponsor · 2026-10-30

NOT_YET_RECRUITING

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)NCT07393555 · lead sponsor · 2026-08-07

NOT_YET_RECRUITING

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN StudyNCT05568472 · lead sponsor · 2023-03-29

ACTIVE_NOT_RECRUITING

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyNCT05633602 · lead sponsor · 2023-03-14

ACTIVE_NOT_RECRUITING

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung CancerNCT05364645 · lead sponsor · 2022-07-25

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT05096663 · lead sponsor · 2022-03-15

ACTIVE_NOT_RECRUITING

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain MetastasesNCT04647916 · lead sponsor · 2021-06-08

ACTIVE_NOT_RECRUITING

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT04625647 · lead sponsor · 2021-04-16

ACTIVE_NOT_RECRUITING

Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)NCT04496739 · lead sponsor · 2020-10-23

ACTIVE_NOT_RECRUITING

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT04267913 · lead sponsor · 2020-09-05

S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung CancerNCT04155034 · lead sponsor · 2020-05-04

ACTIVE_NOT_RECRUITING

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)NCT04268550 · lead sponsor · 2020-04-08

ACTIVE_NOT_RECRUITING

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)NCT04173507 · lead sponsor · 2020-02-14

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)NCT03971474 · lead sponsor · 2019-05-28

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With CancerNCT03939481 · lead sponsor · 2019-05-14

ACTIVE_NOT_RECRUITING

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT03845296 · lead sponsor · 2019-04-16

Lung-MAP S1400K: c-MET PositiveNCT03574753 · lead sponsor · 2018-03-16

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerNCT03373760 · lead sponsor · 2017-11-30

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerNCT03377556 · lead sponsor · 2017-03-03

S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)NCT02728596 · lead sponsor · 2016-10-07

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02785952 · lead sponsor · 2015-12-29

ACTIVE_NOT_RECRUITING

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung CancerNCT02438722 · lead sponsor · 2015-05-07

Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesNCT02785913 · lead sponsor · 2014-11-01

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02965378 · lead sponsor · 2014-10-01

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02785939 · lead sponsor · 2014-09-01

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After CrizotinibNCT02134912 · lead sponsor · 2014-08-01

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02766335 · lead sponsor · 2014-07-31

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02154490 · lead sponsor · 2014-07-08

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesNCT02926638 · lead sponsor · 2014-06-16

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast CancerNCT02137837 · lead sponsor · 2014-05-01

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerNCT01674140 · lead sponsor · 2013-09-12

ACTIVE_NOT_RECRUITING

S1204, Viral Screening in Newly Diagnosed Cancer PatientsNCT01946516 · lead sponsor · 2013-08-29

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone TherapyNCT01598298 · lead sponsor · 2013-05-15

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate CancerNCT01809691 · lead sponsor · 2013-03-08

S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast CancerNCT01535066 · lead sponsor · 2012-05-16

S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast CancerNCT01515800 · lead sponsor · 2012-05-01

S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer SurvivorsNCT01453452 · lead sponsor · 2012-03-01

S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone ThpyNCT01385137 · lead sponsor · 2012-02-01

S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib HydrochlorideNCT01416688 · lead sponsor · 2011-11-15

S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast CancerNCT01097278 · lead sponsor · 2011-11-01

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone TherapyNCT01309672 · lead sponsor · 2011-08-09

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast CancerNCT00856492 · lead sponsor · 2010-04-01

S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and GoserelinNCT01120262 · lead sponsor · 2010-02-01

S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing ChemoNCT00775645 · lead sponsor · 2009-09-01

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung CancerNCT00946712 · lead sponsor · 2009-07-15

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin LymphomaNCT00822120 · lead sponsor · 2009-07-01

S9313B Study of Tumor Tissue Samples From Women With Early-Stage Breast Cancer Enrolled on Clinical Trial SWOG-9313NCT00949013 · lead sponsor · 2009-01-01

Drugs studied in this sponsor's trials

97 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing SWOG Cancer Research Network as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

docetaxel29

paclitaxel19

cisplatin14

carboplatin13

cyclophosphamide13

doxorubicin hydrochloride11

etoposide11

bicalutamide9

docetaxel RxCUI 72962 · Lead sponsor in 21 linked trial(s) · 4 currently recruiting 29 trials paclitaxel RxCUI 56946 · Lead sponsor in 14 linked trial(s) · 1 currently recruiting 19 trials cisplatin RxCUI 2555 · Lead sponsor in 9 linked trial(s) · 0 currently recruiting 14 trials carboplatin RxCUI 40048 · Lead sponsor in 13 linked trial(s) · 3 currently recruiting 13 trials cyclophosphamide RxCUI 3002 · Lead sponsor in 9 linked trial(s) · 1 currently recruiting 13 trials doxorubicin hydrochloride RxCUI 142433 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 11 trials etoposide RxCUI 4179 · Lead sponsor in 9 linked trial(s) · 1 currently recruiting 11 trials bicalutamide RxCUI 83008 · Lead sponsor in 5 linked trial(s) · 1 currently recruiting 9 trials tamoxifen citrate RxCUI 40137 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 9 trials anastrozole RxCUI 84857 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 7 trials prednisone RxCUI 8640 · Lead sponsor in 7 linked trial(s) · 2 currently recruiting 7 trials erlotinib hydrochloride RxCUI 477320 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 6 trials flutamide RxCUI 4508 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 6 trials goserelin acetate RxCUI 203146 · Lead sponsor in 5 linked trial(s) · 1 currently recruiting 6 trials gemcitabine hydrochloride RxCUI 236234 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 5 trials leuprolide acetate RxCUI 203217 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 5 trials exemestane RxCUI 258494 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 4 trials goserelin RxCUI 50610 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 4 trials letrozole RxCUI 72965 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 4 trials nilutamide RxCUI 31805 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 4 trials pemetrexed RxCUI 68446 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials pemetrexed disodium RxCUI 282443 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 4 trials dexamethasone RxCUI 3264 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting 3 trials everolimus RxCUI 141704 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials

Sponsor roles

lead sponsor130

collaborator40

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.